Bayer Healthcare Pharmaceuticals has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents for cancer drug Stivarga (regorafenib).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
15 March 2019 Doctors’ handwriting poses a significant challenge to the registration of pharmaceutical trademarks, according to a senior counsel at German pharmaceutical company Bayer.
15 March 2019 Doctors’ handwriting poses a significant challenge to the registration of pharmaceutical trademarks, according to a senior counsel at German pharmaceutical company Bayer.
15 March 2019 Doctors’ handwriting poses a significant challenge to the registration of pharmaceutical trademarks, according to a senior counsel at German pharmaceutical company Bayer.
